Sign up to save your podcasts
Or
Share Calming Overactive Immune Response and Reducing Inflammation with TYK2 Inhibition in Psoriasis
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Calming Overactive Immune Response and Reducing Inflammation with TYK2 Inhibition in Psoriasis
CME credits: 0.25
Valid until: 30-04-2027
Claim your CME credit at https://reachmd.com/programs/cme/calming-overactive-immune-response-and-reducing-inflammation-with-tyk2-inhibition-in-psoriasis/50978/
There have been exciting advances in the treatment of psoriasis. Join Drs. April Armstrong and Melinda Gooderham for this expert discussion to learn about the most recent data on TKY2 inhibitors, presented at the American Academy of Dermatology Annual Meeting in Denver, Colorado.
=
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.25
Valid until: 30-04-2027
Claim your CME credit at https://reachmd.com/programs/cme/calming-overactive-immune-response-and-reducing-inflammation-with-tyk2-inhibition-in-psoriasis/50978/
There have been exciting advances in the treatment of psoriasis. Join Drs. April Armstrong and Melinda Gooderham for this expert discussion to learn about the most recent data on TKY2 inhibitors, presented at the American Academy of Dermatology Annual Meeting in Denver, Colorado.
=